What is Grifols worth?
Grifols, a global healthcare company specializing in plasma-derived medicines, had an estimated market capitalization or net worth of approximately $6.62 billion as of July 24, 2026. This valuation reflects the market's assessment of the company's equity and its various business operations in the biopharmaceutical sector. Over the 12-month period leading up to late July 2026, the company's market capitalization saw a slight decrease of about 2.31%. Investors and financial analysts continuously track this figure as a primary metric for assessing the company's overall market standing, competitiveness in the plasma industry, and its ability to manage its enterprise value amidst shifting healthcare demands.
Related FAQs
Yes, Grinnell State Bank provides a comprehensive range of lending services designed to meet the diverse needs of the individuals, families, and businesses within its community.
While GlobalFoundries frequently earns positive coverage and selective buy recommendations from Wall Street research firms, it rarely achieves a unanimous strong buy consensus due to the inherently cyclical nature of contract semiconductor manufac...
Grifols frequently attracts mixed evaluations from healthcare and pharmaceutical equity analysts, who balance its global leadership in plasma-derived therapeutics against its leveraged balance sheet structure and historical financial transparency ...
Grifols operates as a critical global healthcare enterprise dedicated to manufacturing essential plasma-derived medicines that treat rare, chronic, and life-threatening conditions worldwide.
Grifols operates as a publicly traded multinational pharmaceutical and biotechnology corporation, with its shares listed on Spanish stock exchanges and American Depositary Shares traded on the Nasdaq global market under the ticker symbol GRFS.
Grifols, S.A. operates as a global healthcare leader specializing in plasma-derived biological medicines and diagnostic systems, placing it in direct competition with major pharmaceutical enterprises.
The Chief Executive Officer of Grifols, Nacho Abia, receives an annual base salary set at EUR 2.0 million, as part of a total annual compensation package that scales up to approximately EUR 3.52 million.
Executive management positions, including Vice President of Global Plasma Operations, Senior Director of Medical Affairs, and specialized Head of Biopharmaceutical Research, represent the highest-paying roles within Grifols.
Grifols has been active in financial headlines regarding corporate restructuring, governance enhancements, strategic partnerships, and debt-reduction initiatives involving its plasma-derived medicines business.
Grifols, S.A. (GRFS) equity consensus forecasts among biotechnology and healthcare analysts reflect a cautious "Reduce" to "Hold" rating, with average price targets positioning near $10 per share.
Broad market equity forecasts and macroeconomic valuation models projecting toward 2026 synthesize corporate earnings growth, resilient consumer demand, and anticipated monetary policy adjustments across major global exchanges.
Grifols, S.A.
Grifols USA LLC maintains its primary United States corporate headquarters and administrative base in Los Angeles, California.